Form 4: CRISPR Therapeutics CFO Receives Equity Grant

CRISPR Therapeutics CFO Raju Prasad was granted 19,500 restricted stock units vesting in November 2028.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics, received a grant of 19,500 restricted stock units (RSUs).
• The grant was issued on May 29, 2026.
• The RSUs represent a contingent right to receive one common share per unit upon vesting.
• The entire award is scheduled to vest on November 29, 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel through a multi-year vesting schedule.

Negatives

• Potential for future shareholder dilution upon the eventual issuance of common shares related to these RSUs.

Risks

• Market volatility affecting the future value of the equity grant.
• Retention risk if the executive departs prior to the November 2028 vesting date.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation disclosure.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure long-term alignment with R&D milestones and clinical trial progress.

Comparison to Industry Standards

• The use of multi-year cliff vesting (2.5 years in this case) is consistent with standard executive compensation packages in the biotech industry.
• Granting RSUs as a component of total compensation is common practice for NASDAQ-listed life sciences companies.

Stakeholder Impact

• Shareholders: Minor dilution impact upon future vesting.
• Executive: Increased long-term financial incentive tied to company performance.

Next Steps

• Vesting of the 19,500 RSUs on November 29, 2028.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Insider Trading, Form 4, Equity Compensation, CFO